Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus CLINDAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus CLINDAGEL.
BACTROBAN vs CLINDAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, disrupting peptide chain initiation. It may also exhibit anti-inflammatory and immunomodulatory effects via inhibition of neutrophil chemotaxis and phagocytosis.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Apply thin layer to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
2-3 hours in patients with normal renal function; clinically significant accumulation may occur in severe hepatic impairment.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Approximately 10% of the dose is excreted renally as unchanged drug; the remainder is hepatically metabolized and excreted in bile and feces. Renal clearance accounts for <1% of total clearance.
Category C
Category C
Topical Antibiotic
Topical Antibiotic